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Reduction of Huntington’s Disease
RNA Foci by CAG Repeat-Targeting
Reagents
Martyna O. Urbanek, Agnieszka Fiszer and Wlodzimierz J. Krzyzosiak*
Department of Molecular Biomedicine, Institute of Bioorganic Chemistry, Polish Academy of Sciences, Poznan, Poland
In several human polyglutamine diseases caused by expansions of CAG repeats in
the coding sequence of single genes, mutant transcripts are detained in nuclear RNA
foci. In polyglutamine disorders, unlike other repeat-associated diseases, both RNA
and proteins exert pathogenic effects; therefore, decreases of both RNA and protein
toxicity need to be addressed in proposed treatments. A variety of oligonucleotide-
based therapeutic approaches have been developed for polyglutamine diseases, but
concomitant assays for RNA foci reduction are lacking. Here, we show that various
types of oligonucleotide-based reagents affect RNA foci number in Huntington’s disease
cells. We analyzed the effects of reagents targeting either CAG repeat tracts or specific
HTT sequences in fibroblasts derived from patients. We tested reagents that either
acted as translation blockers or triggered mRNA degradation via the RNA interference
pathway or RNase H activation. We also analyzed the effect of chemical modifications of
CAG repeat-targeting siRNAs on their efficiency in the foci decline. Our results suggest
that the decrease of RNA foci number may be considered as a readout of treatment
outcomes for oligonucleotide reagents.
Keywords: Huntington’s disease, polyglutamine diseases, RNA foci, RNA toxicity, siRNA, antisense
oligonucleotides
INTRODUCTION
A group of human neurodegenerative diseases is caused by the expansion of CAG repeats located
in the coding sequence of single functionally unrelated genes; these disorders are called polyQ
diseases. The most thoroughly analyzed member of this group of disorders is HD, caused by
expanded CAG repeats in the first exon of the HTT gene. Both RNA and protein products from
the mutant allele are proposed to be involved in the pathogenic process; therefore, the most
promising therapeutic approaches are designed to target the mutant transcripts. Mutant mRNA
is partially or temporarily retained in the nucleus within splicing speckles, as shown in multiple
types of cellular models of polyQ diseases (De Mezer et al., 2011; Urbanek et al., 2016). Increased
retention of mutant RNA in the nucleus is associated with compromised functions of proteins
that bind to mutant RNA (Jazurek et al., 2016); examples of such malfunctions are alternative
splicing abnormalities (Mykowska et al., 2011; Sathasivam et al., 2013; Cabrera and Lucas, 2016)
and other gene expression alterations (Sharma and Taliyan, 2015). For that reason, RNA foci are
increasingly considered undesired toxic structures, rather than a protective cellular self-defense
Abbreviations: ASO, antisense oligonucleotide; FISH, fluorescence in situ hybridization; HD, Huntington’s disease; IF,
immunofluorescence; LNA, locked nucleic acid; ON, oligonucleotide; polyQ, polyglutamine; siRNA, small interfering RNA.
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mechanism. RNA foci were shown in various types of cellular
models of HD, including fibroblasts, lymphoblasts, and neuronal
progenitors (Urbanek and Krzyzosiak, 2016).
Various approaches have been used to decrease RNA foci
in different repeat expansion diseases, including myotonic
dystrophy type 1 (DM1), myotonic dystrophy type 2, fragile
X–associated tremor/ataxia syndrome, and amyotrophic
lateral sclerosis and frontotemporal dementia (ALS-FTD)
(Supplementary Table S1) (Langlois et al., 2003; Disney et al.,
2012; Nguyen et al., 2014; Rzuczek et al., 2014; Su et al., 2014).
The most widely analyzed foci-targeting factors are small
molecules that decrease the nuclear accumulation of mutant
RNA and significantly reduce pathological interactions of
mutant RNAs with proteins in the case of DM1 (Warf et al.,
2009; Jahromi et al., 2013a,b; Hoskins et al., 2014; Ketley et al.,
2014; Wojciechowska et al., 2014; Wong et al., 2014). However,
various ON reagents have also been used successfully for DM1
and ALS-FTD (Mulders et al., 2009; Wheeler et al., 2009,
2012; François et al., 2011; Larsen et al., 2011; Lee et al., 2012;
Lagier-Tourenne et al., 2013; Sareen et al., 2013; Sobczak et al.,
2013; Wojtkowiak-Szlachcic et al., 2015). Multiple therapeutic
approaches have been proposed for polyQ diseases (reviewed
in Fiszer and Krzyzosiak, 2014; Keiser et al., 2016), but their
effects on nuclear RNA foci have been barely analyzed. To date,
only a single recent report refers to foci reduction, showing that
20-nt-long LNA-modified ON composed of CTG units disrupts
CAG RNA foci in an HD model (Rué et al., 2016).
The ON-based reagents tested to develop therapeutic
approaches for polyQ diseases include mostly siRNAs and ASOs.
siRNAs localize mainly in the cytoplasm, which is their primary
site of action. However, siRNAs can also function in the nucleus
(Robb et al., 2005; Gagnon et al., 2014), reviewed in Kalantari
et al. (2016). In contrast, ASO reagents are thought to function
mainly in the nucleus, activating RNase H, although, they can also
be active in the cytoplasm (Castanotto et al., 2015; Liang et al.,
2015). The localization of reagents may determine their cellular
functionality, especially when target transcripts are captured in
distinct structures.
An attractive therapeutic approach is targeting the mutation
site directly in transcripts implicated in polyQ diseases. In order
to achieve high preference in the silencing of mutant alleles,
CAG repeat-targeting siRNAs have been modified to form base
mismatches with the target sequence and induce a mechanism
similar to that of miRNAs (Hu et al., 2010; Fiszer et al., 2011,
2013, 2016; Yu et al., 2012; Liu et al., 2013). In mutation-targeting
approach also oligomers acting as translational blockers were
developed as potential therapeutics for HD and spinocerebellar
ataxia type 3 (SCA3) (Hu et al., 2009; Fiszer et al., 2012). For
targeting specific sequence of huntingtin mRNA, siRNAs, and
ASOs were successfully tested in HD mouse models (Wang et al.,
2005; DiFiglia et al., 2007; Boudreau et al., 2009; Carroll et al.,
2011; Kordasiewicz et al., 2012; Ostergaard et al., 2013; Southwell
et al., 2014).
In this study, we analyzed the influence of ON-based reagents
on RNA foci observed in HD fibroblasts. We aimed to establish
whether activity pathways of ONs affect their potential to
decrease RNA foci and whether ASO ONs, RNAi triggers, or LNA
blocker are more effective in decreasing nuclear foci. We also
aimed to compare the activity of different chemically modified
ONs and to examine the correlation between their inhibitory
activity on RNA and protein expression and their potential to
decrease RNA foci number. To gain deeper insight into the
mechanism of ON action we considered following functionality
scenarios:(I) non-functional reagents that neither affect the size,
number, and morphology of foci nor protein or RNA levels;
(II) reagents that decrease RNA and protein levels, but do not
affect RNA foci, indicating the degradation of RNA only in the
cytoplasm; (III) reagents that decrease only protein levels, acting
as translation blockers; (IV) reagents that decrease RNA foci as
well as protein and RNA levels, indicating the degradation of
transcripts in both the nucleus and cytoplasm; (V) reagents that
decrease the foci number, but increase RNA and protein levels,
suggesting the release of transcripts from foci to the cytoplasm,
without further degradation; and (VI) reagents that increase the
number of RNA foci by triggering the retention of RNA in the cell
nucleus.
MATERIALS AND METHODS
Cell Culture
Human fibroblasts (control: GM07492; HD: GM04281, 17/68
CAG in HTT gene, HD2: GM09197, 21/151 CAG in HTT
gene) were obtained from Coriell Repository (Camden, NJ,
USA). Fibroblasts were cultured in Minimal Essential Medium
(Sigma–Aldrich, St. Louis, MO, USA) with 10% Fetal Bovine
Serum (Sigma–Aldrich) supplemented with GlutaMAX (Life
Technologies, Carlsbad, CA, USA), non-essential amino acids
(Sigma–Aldrich), and Antibiotic Antimycotic Solution (Sigma–
Aldrich) at 37◦C. All cell cultures were checked for mycoplasma
contamination.
Oligonucleotides and Cell Transfection
Oligonucleotide were synthesized by Future Synthesis (Poznan,
Poland) or IDT (Coralville, IA, USA), and duplexes were
annealed according to the manufacturer’s instructions. The LNA
oligomer was synthetized by Exiqon (Vedbæk, Denmark). The
sequences of the synthetic ONs and oligomer used in this study
are presented in Table 1.
Cell transfections were performed using Lipofectamine 2000
(Life Technologies) according to the manufacturer’s instructions.
The reagents were transfected at 50 nM, unless stated otherwise
in figure legends. Oligonucleotide treatment lasted for 4 h; after
that time medium was changed. Material for subsequent analyses
was collected after 48 h. For fixation, cells were seeded directly on
cover slips prior to transfection. The transfection efficiency was
monitored using BlockIT fluorescent siRNA (Life Technologies).
RNA Fluorescence In situ Hybridization
and Immunofluorescence
Fluorescence in situ hybridization and IF procedures were
performed as described previously (Urbanek and Krzyzosiak,
2016). Briefly, cells were fixed in 4% paraformaldehyde at 4◦C
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TABLE 1 | The nucleotide sequences and chemical modifications of the ONs tested in this study.
Oligonucleotide (5′–3′) Main mechanism of
action
Comment/Reference
CAG repeat tract-specific
A2 AS: GCUGCUGCAGCUGCUGCUGCU RNAi/miRNA Fiszer et al., 2013
G2 AS: GCUGCUGCGGCUGCUGCUGCU RNAi/miRNA Fiszer et al., 2013
A2F AS: 5′P GCUGCUGCAGCUGCUGCUGCU RNAi/miRNA Fiszer et al., 2016
A2M AS: 5′P G∗C∗UG∗CU∗GC∗AG∗CU∗GC∗U∗G∗C∗U∗G∗C∗U RNAi/miRNA Modifications pattern corresponding to
Yu et al., 2012/Fiszer et al., 2016
CAG/CUG AS: CUGCUGCUGCUGCUGCUGCUGC
SS: CAGCAGCAGCAGCAGCAGCAGC
RNAi
LNA CTG (C)(T)(G)(C)(T)(G)(C)(T)(G)(C) Blocker Corresponding to CAG LNA tested by
Wojtkowiak-Szlachcic et al., 2015
ASO CTG C∗U∗G∗C∗U∗g∗c∗t∗g∗c∗t∗g∗c∗t∗g∗C∗U∗G∗C∗U RNaseH
HTT sequence-specific
siHTT AS: ACUUGAGGGACUCGAAGGCCU SS: GGCUUCGAGUCCCUCAAGUCC RNAi Fiszer et al., 2013
ASO HTT U∗C∗U∗C∗U∗a∗t∗t∗g∗c∗a∗c∗a∗t∗t∗C∗C∗A∗A∗G RNaseH Carroll et al., 2011
Other
siLuc AS: UCGAAGUAUUCCGCGUACGUU SS: CGUACGCGGAAUACUUCGAUU RNAi siRNA with no target in cells
BLOCK-iT Fluorescent Oligo (Life Technologies) Control Transfection efficiency control
Base substitutions in CAG repeat tract-specific ONs, resulting in mismatch formation with the target sequence, are marked in bold. Legend for the composition and
chemical modifications of ONs: N – RNA; n – DNA; 5′P – 5′-phosphorylation; N – 2′OMe; ∗ – PTO; N – 2′F; (N) – LNA.
for 30 min. Permeabilization was performed with 2% acetone
for 5 min, and overnight incubation in 70% EtOH. Prior to
hybridization, cells were prehybridized in 30% formamide, 2x
SSC buffer for 30 min at RT. Hybridization was performed
in hybridization buffer (30% formamide, 2x SSC, 200 ng/ml
ssDNA, 0.02% BSA, 10% dextran sulfate, 2 mM vanadyl-
ribonucleoside, 2 nM probe) at 37◦C overnight. Washing
was performed with 30% formamide, 2x SSC and 1x SSC at
RT. For biotin-labeled probes washings were performed only
in 1x SSC and subsequently samples were blocked with 1%
BSA buffer for 1 h at RT and incubated with IgG Fraction
Monoclonal Mouse Anti-Biotin antibody (1:200, 200-542-211,
Jackson ImmunoResearch; West Grove, PA, USA) overnight
at 4◦C. For signal enhancement samples were additionally
incubated for 1 h with AffiniPure F(ab′)2 Fragment Donkey
Anti-Mouse IgG (H+L) antibody labeled with Alexa488 (1:500,
715-546-150, Jackson ImmunoResearch; West Grove, PA, USA).
For RNase treatment, cells were subjected to 0.01 µg/ml RNase
A for 1.5 h after the permeabilization step. For IF, samples
were blocked with 1% BSA buffer for 1 h at RT, incubated with
primary anti-huntingtin antibody (1:200, MAB2166, Millipore)
at 4◦C overnight and with secondary antibody AffiniPure F(ab′)2
Fragment Donkey Anti-Mouse IgG (H+L) antibody labeled
with Alexa488 (1:500) for 1 h. For combined RNA FISH and
IF, first, FISH was performed with only 1x SSC washings.
Next, samples were blocked with 1% BSA for 30 min and
incubated with anti-huntingtin antibody for 3 h and secondary
antibody for 45 min. For endosomes visualization anti-Rab5
(1:200, 12666T, Cell Signaling Technology; Danvers, MA, USA)
and anti-EEA1 (1:100, 12666T, Cell Signaling Technology)
antibodies and secondary antibody AffiniPure F(ab′)2 Fragment
Donkey Anti-Rabbit IgG (H+L) antibody labeled with Alexa488
(1:500, 711-546-152, Jackson ImmunoResearch) were used.
Nuclei were imaged with SlowFade Gold with DAPI (Life
Technologies). Images were captured with a Leica SP5 confocal
microscope.
For CAG-specific ONs detection in cells we used DNA probe
Cy3-(CAG)6CA (Metabion, Germany), for foci imaging we
used either LNA-modified DNA probe Cy3-(CTG)6CT (Exiqon,
Denmark) or three HTT-specific 5′-Biotin-labeled DNA probes:
GGTAAAAGCAGAACCTGAGCGGCCGTCCATCTTGGACC
CGT, TCGAAGGCCTTCATCAGCTTTTCCAGGGTCGCCAT,
TCCATAGCGATGCCCAGAAGTTTCTGAAATTCTGGAG
(Metabion).
Western Blot Analysis
The western blot analysis for the HTT protein (17/68Q tract)
was performed as previously described (Fiszer et al., 2011).
Briefly, 30 µg of total protein was run on a Tris-acetate
sodium dodecyl sulfate (SDS)-polyacrylamide gel (1.5 cm,
4% stacking gel/4.5 cm, 5% resolving gel, acrylamide:bis-
acrylamide ratio of 49:1) in XT Tricine buffer (Bio-Rad,
Hercules, CA, USA) at 130 V in an ice-water bath. Subsequently,
the proteins were wet-transferred to a nitrocellulose membrane
(Sigma–Aldrich). All of the immunodetection steps were
performed using the SNAPid system (Millipore). The primary
antibodies anti-huntingtin (1:1000, MAB2166, Millipore) and
anti-plectin (1:1000, ab83497, Abcam, Cambridge, UK) and
secondary antibodies anti-mouse HRP-conjugate (1:2000,
A9917, Sigma–Aldrich) and anti-rabbit HRP-conjugate (1:2000,
711-035-152, Jackson ImmunoResearch) were used in a
PBS/0.1% Tween-20 buffer containing 0.25% non-fat milk.
The immunoreaction was detected using WesternBright
Quantum HRP Substrate (Advansta, Menlo Park, CA,
USA). The protein bands were scanned directly from the
membrane using a camera and were quantified using Gel-Pro
Analyzer.
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RNA Isolation and Reverse
Transcription-Polymerase Chain
Reaction
Total RNA was isolated from fibroblast cells using TRIzol
reagent (Sigma–Aldrich) and a Direct-zol Kit (Zymo Research,
Irvine, CA, USA) according to the manufacturer’s instructions.
For isolation of RNA fractions Cytoplasmic and Nuclear RNA
Purification kit (Norgen Biotek, Corp., Thorold, ON, Canada)
was used according to the manufacturer’s instructions. The RNA
concentration was measured using a DeNovix spectrophotometer
(Wilmington, DE, USA). An amount of 500 ng of total RNA or
200 ng of fractionated RNA was reverse transcribed at 55◦C using
Superscript III (Life Technologies) and random hexamer primers
(Promega, Madison, WI, USA). cDNA was used for qPCR using
LightCycler 480 SYBR Green I Master (Roche, Basel, Switzerland)
with denaturation at 95◦C for 10 min, followed by 45 cycles
of denaturation at 95◦C for 10 s, annealing at 60◦C for 15 s,
and elongation at 72◦C for 20 s, with HTT, GAPDH, or U6-
specific primers (sequences are listed in Supplementary Table S2)
on the Light Cycler 480 II (Roche). Data pre-processing and
normalization were performed using LightCycler 480 SW 1.5.1
software.
Image Analysis
ImageJ software (Fiji distribution) was used for image analysis.
Images were adjusted with respect to brightness, contrast, and
smooth effects. For the statistical analysis of images, a Python
script for ImageJ was prepared.
Number of Foci Estimation
For estimation of RNA foci number Python (Jython) script was
prepared for ImageJ. First, analyzed area was restricted to the
nucleus using DAPI signal. Next, after adjusting threshold for
the red signal (from probe), image was converted to mask and
particles were analyzed (with restrictions to minimal size of
foci but accepting all shapes with circularity index). Each image
represented single cell. Results for group of images were saved in
text file for statistical analyses.
Quantity of Nuclear Transcripts
For estimation of quantity of nuclear CAG transcripts Python
(Jython) script was prepared for ImageJ. First, analyzed area was
restricted to the nucleus using DAPI signal. Next, mean intensity
signal (red canal from the probe) from the nucleus was calculated.
Each image represented single cell. Results for group of images
were saved in text file for statistical analyses.
Statistical Analysis
All experiments were repeated at least three times. The statistical
significance of changes in gene expression levels (real-time PCR,
western blotting, and IF level) was assessed using a one-sample
t-test, with an arbitrary value of 1 assigned to cells treated
with control siRNA (siLUC). Selected data were compared using
an unpaired t-test with Welch’s correction to assess the allele-
selectivity of silencing (normal vs. mutant allele silencing). The
statistical significance of the number of foci, nuclear RNA signal
and percent of aggregate-positive cells was assessed using a one-
way ANOVA and multiple comparisons testing with post hoc
Dunnett’s tests. For FISH and IF analyses, at least 30 cells were
analyzed for each experimental condition. p-values of<0.05 were
considered significant.
RESULTS
Selection and Design of Oligonucleotides
We used a set of chemically synthesized ONs that differed with
regard to their (I) targeted sequence (specific HTT sequence
or CAG repeats), (II) anticipated mechanism of activity (RNAi-
based, RNase H-inducing, and a “blocker”), and (III) pattern of
chemical modification (pure RNA ONs and RNAs containing
2′-fluoro (2′F), 2′-O-methylo (2′OMe), and phosphorothioate
(PTO) modifications, DNA gapmers with 2′OMe and PTO, as
well as LNA oligomer). All ON sequences are presented in Table 1
with references if they were used in previous studies. Specifically,
we used siRNA and ASO targeting HTT-specific sequences
(siHTT and ASO HTT, respectively) and a set of CAG repeat-
targeting ONs: unmodified RNA duplex (CAG/CUG), miRNA-
like siRNAs with single mismatches (A2 and G2), chemically
modified siRNA (A2F and A2M), antisense oligonucleotide (ASO
CTG) and a short LNA blocker (LNA CTG) (Figure 2A).
CAG-Targeting RNA Interference
Reagents Localize Predominantly to the
Cytoplasm and Antisense ONs to the
Nucleus
First, we aimed to determine the cellular distribution of ONs
targeting CAG repeat sequences. Selected siRNAs (CAG/CUG,
A2, G2, A2F, and A2M), ASO CTG, and LNA CTG were delivered
by lipid-based transfection. After 48 h, cells were fixed and
small-RNA FISH was performed using probes that interact with
the ONs in a 1:1 stoichiometry. However, we were not able to
visualize LNA reagents owing to their short length. First, we
obtained images of reagents in control fibroblasts (Figure 1A).
We observed predominantly cytoplasmic localization of RNA
interference reagents, both unmodified and chemically modified.
Owing to the differences in binding strengths of the probes to
various ONs, we did not quantify differences between reagents.
The ONs mainly localized to cytoplasmic vesicles (Figure 1B),
similar to the localization observed for control fluorescent siRNA,
BlockIT (data not shown). Observed ONs did not localize within
endosomes marked with EEA1 and Rab5 proteins showing
that these are probably vesicles formed by the lipofection
(Supplementary Figures S1A,B). It is worth noting that using
this experimental approach, we could observe only cellular spots
that contained multiple ON molecules, but not the localization
of single molecules that could represent sites of interactions
with target sequences. We also observed the passenger strand of
CAG/CUG, which showed similar localization to that of the guide
strand (Figure 1C). ASO localized within both the cytoplasm
and nucleoplasm; however, a strong bias toward the nucleus was
observed. Non-transfected cells and cells transfected with control
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FIGURE 1 | Localization of siRNAs and ASOs targeting CAG repeat tract in fibroblasts. (A) Representative RNA FISH images of the control fibroblast cell line
after transfection with indicated ONs are presented. (B) Localization of A2 reagent in control fibroblasts. (C) Localization of the passenger strand from CAG/CUG
duplex in control fibroblasts. (D) Representative RNA FISH images of the HD fibroblast cell line after transfection with indicated ONs. DAPI staining (blue), reagents
(red); bar = 10 µm.
siRNA siLUC were used as negative controls. Next, we examined
whether the CAG repeat-expanded tract present in HD cells
affects the localization of reagents targeting the CAG sequence.
We did not observe significant differences in localization between
HD and control fibroblasts, indicating that the presence of the
mutation in cells does not alter reagent localization (Figure 1D).
Additional Assays to Estimate Cellular
Effects of ON Treatments
In our earlier studies we defined the effectiveness of ON
treatment at the RNA level using RT-PCR (separate analyses
for normal and mutant alleles) and at the protein level using
western blot (Fiszer et al., 2011, 2013, 2016). To monitor
treatment outcomes more broadly, we added in the current study
a microscopic analyses of CAG RNA foci and huntingtin levels
and localization. We used a CTG probe that was demonstrated in
previous studies (Urbanek and Krzyzosiak, 2016) to successfully
visualize RNA foci in cellular models of polyQ diseases
(Figure 2B). Both analyzed HD lines demonstrated nuclear RNA
foci, which were observed in about 50% cells. RNA foci were
not detected after RNase treatment (Supplementary Figure S2).
As shown for LNA reagents, for which their binding to repeat
sequences may block subsequent RT-PCR (Rué et al., 2016),
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FIGURE 2 | Imaging systems developed for monitoring effects
triggered by ONs in cells. (A) Scheme of HTT mRNA with place of probes
binding (red: CTG probe, green: HTT-specific probes) and ONs binding (navy:
CAG-targeting ONs, violet: siHTT, turquoise: ASO HTT). Scheme shows also
the binding sites of the primers used for PCR amplification on the junction of
HTT exon 64 and 65. Gray boxes represent exonic sequence and the black
lines represents introns. (B) RNA foci visualized with CAG-specific probe in
HD cells with mask used to count RNA foci, bar = 20 µm. (C) RNA foci
visualized with HTT-specific probes in HD cells, bar = 20 µm.
(D) Huntingtin-specific IF to visualize protein levels and aggregates in HD cells,
bar = 25 µm. Representative images of control, HD (17/68 CAG), and HD2
(21/151 CAG) fibroblast cells are presented. DAPI staining (blue), HTT
transcripts (green), HTT protein (green), CAG repeats (red).
we demonstrated that the reagents did not interfere with the
RNA FISH procedure by visualizing HTT mRNA with HTT
sequence-specific probes. Probes targeting the first exon of HTT
mRNA were used to successfully visualize RNA foci in HD
fibroblasts. In control fibroblasts, the signal was rather uniform
within the nucleoplasm and cytoplasm, with increased signals
strength observed in nucleoli (Figure 2C). An additional feature
of HD that may serve as an indicator of an effective therapeutic
approach is the presence of HTT protein aggregates. We observed
huntingtin aggregates in the cytoplasm and nucleus in both
HD fibroblast cell lines, and no such aggregates were visible in
the control cell line (Figure 2D). Thus in addition to western
blotting, IF may be used to observe protein level changes resulting
from ON treatment.
Effects of ON-Based Reagents on HTT
Expression at the mRNA and Protein
Levels
We investigated the silencing of HTT expression at the
mRNA and protein levels using selected ONs under the same
experimental conditions as used for microscopic analyses, i.e.,
48 h after the transfection of HD fibroblasts with 50 nM ONs.
We assessed total HTT mRNA levels using qRT-PCR and primers
located downstream the CAG repeat tract (Figures 2A, 3A). The
most significant decreases in HTT mRNA were observed for
siHTT (to ∼40% of the control level) and for both ASOs (to
∼65% of the control level). CAG/CUG reagent decreased level
of HTT mRNA to ∼85%. A separate analysis of HTT alleles
by semi-quantitative RT-PCR revealed a similar general trend
of HTT silencing by these ONs and there was no indication
of allele-selective inhibition by ASO reagents (data not shown).
At the selected time point, we did not observe decrease in
HTT mRNA level by A2, G2, A2F, and A2M ONs. Additionally,
for selected set of ONs we performed RNA fractionation to
analyze changes in nuclear and cytoplasmic transcript level
(Supplementary Figures S3A,B). We tested siHTT, A2, ASO
HTT, and ASO CTG in this assay. The results were generally
consistent with qRT-PCR for total transcript level described
above. siHTT caused lowering of HTT mRNA already in the
nucleus (to ∼70%) but more prominent effects were observed in
the cytoplasm what in total resulted in HTT mRNA decrease to
∼25%. For A2 we observed slight increase of HTT transcript in
the nucleus and slight decrease in the cytoplasm. As expected,
the effects of ASOs activity were mainly nuclear as these ONs
decreased HTT mRNA level to ∼45% already in the nucleus.
For all nine ONs we performed western blotting to analyze
normal and mutant huntingtin levels separately (Figure 3B). For
ONs that lowered HTT mRNA (siHTT and ASOs), significant
decreases in protein levels were also observed, to ∼25%, ∼30%,
and ∼60% of the control level for siHTT, ASO HTT and ASO
CTG, respectively. Neither siHTT, nor any of the used ASOs
acted in an allele-selective way, decreasing both alleles with
similar strength. Consistent with previous reports, selected CAG
repeat-targeting reagents caused the allele-selective lowering
of huntingtin, with a high preference for the mutant protein
observed for A2, G2, and A2F. Significant allele-selectivity was
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FIGURE 3 | Regulation of HTT expression by ONs. (A) qRT-PCR analysis of total HTT mRNA levels in HD fibroblasts after transfection with 50 nM of the
indicated ONs. HTT level was normalized to the GAPDH level. (B) Western blot analysis of normal and mutant huntingtin levels for the same experiment as in (A).
The level of HTT alleles was normalized to plectin level. In all samples expression level was referred to HTT expression in cells transfected with siLUC (set as 1). NT –
non-treated cells. The p-value is indicated with an asterisk (∗p < 0.05); graphs are presented with standard deviation values.
also observed for A2M ON, but not for CAG/CUG siRNA or LNA
CTG.
Effects of ON-Based Reagents on RNA
Foci
Next, we analyzed RNA foci after ONs treatment to investigate
whether mRNAs within the nucleus are accessible to ON
reagents, whether these ONs exert their activity within the
nucleus, and whether they can decrease RNA foci. Our results
showed that not all tested ONs are able to significantly
decrease the number of RNA foci, despite altering the RNA or
protein levels. The results differed for probes used; however, a
similar tendency to reduce number of RNA foci was observed
(Figures 4A,B). Untreated HD fibroblasts had a mean of 12.4
foci per foci-positive cell, in agreement with our previous
reports. Cells treated with siLUC and BlockIT exhibited similar
means, with 11.2 and 14.3 foci per cell, respectively. Most
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FIGURE 4 | Nuclear RNA level and foci number reduction after ON treatment of HD fibroblasts. (A) Representative RNA FISH images of HD fibroblast cells
treated with indicated ONs visualized with CAG-specific probe. (B) Representative RNA FISH images of HD fibroblast cells treated with indicated ONs visualized with
HTT-specific probes. DAPI staining (blue), CAG repeats (red), HTT mRNA (green); bar = 10 µm. (C) Number of RNA foci per cell, calculated from images obtained
using CAG-specific probe (see Number of Foci Estimation). (D) Nuclear level of transcript (represented as mean signal intensity per cell), calculated from RNA FISH
images based on nuclear signal from CAG-specific probe (see Quantity of Nuclear Transcripts). Statistical significance of changes observed after ON treatment was
assessed in reference to measurements obtained for NT (non-treated) cells. The p-value is indicated with an asterisk (∗p < 0.05); graphs are presented with standard
error of mean (SEM) values.
significantly RNA foci-disrupting ONs were A2, with a mean
of 6.6 foci per cell, ASO CTG, with a mean of 6.1, and
LNA CTG, with a mean of 6.8 foci per cell (Figure 4C).
Most of the tested ONs significantly decreased the number of
foci per cell, but with different efficiencies. siHTT, CAG/CUG,
G2, A2F, and A2M reduced foci number to a mean of 7.9,
7.4, 7.3, 7.5, and 8.1 foci per cell, respectively. We did not
observe significant foci alterations using ASO HTT. Next, we
analyzed nuclear signals from the CTG probe (Figure 4D).
All HTT-specific and CAG-specific ONs, except for LNA CTG,
decreased level of detected RNA in the nucleus. siHTT and
CAG/CUG reagents also triggered visible reductions in overall
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FIGURE 5 | Huntingtin level and presence of aggregates measured by
IF after treatment of HD cells with ONs. (A) Level of huntingtin based on
IF performed in HD fibroblasts 48 h after transfection with 50 nM of the
indicated ONs. (B) Representative images showing non-treated and ASO
CTG-treated HD fibroblasts imaged with IF. Bar = 25 µm. (C) Representative
image showing the localization of huntingtin around vesicles after transfection
with ASO CTG. (D) Representative image showing the localization of
huntingtin around the nucleus after transfection with ASO CTG. (E) Percent of
aggregate-positive cells calculated for the same experiment as described in
(A). Statistical significance of changes after ON transfection was assessed in
reference to measurements obtained for NT (non-treated) cells. DAPI staining
(blue), HTT protein (green). Bar = 10 µm. The p-value is indicated with an
asterisk (∗p < 0.05); graphs are presented with SEM values.
signal intensity from the cell. Differences between results
obtained for measurement of nuclear level of transcript with
RNA FISH and qRT-PCR after fractionation (Supplementary
Figure S3A), are probably related to different specificity of the
methods. Next, we compared results from foci analysis with
total RNA level results obtained with qRT-PCR (Figure 3A).
There was no clear correlation between the reduction in RNA
levels and the RNA foci phenotype (Spearman correlation,
p= 0.8603).
Effects of ON-Based Reagents on
Huntingtin Aggregates
To further analyze the therapeutic potential of selected ONs, we
performed IF experiments to detect huntingtin protein (both
normal and mutant) in cells. The results of the microscopic
analysis of HTT protein levels (Figures 5A,B and Supplementary
Figure S5) were in agreement with results obtained by western
blotting (Figure 3B). However, we could additionally observe
differences in protein localization after ON treatment and the
presence and number of mutant protein aggregates. Protein
aggregates were observed in cells with or without RNA foci
showing that there is no connection between formation of
RNA foci and protein aggregates (Supplementary Figure S4).
We observed that after treatment with ASO CTG, the protein
tended to localize around the cytoplasmic vesicles containing
ONs (Figure 5C). Moreover, in a substantial portion of cells,
the protein localized around the nucleus after ON treatment
(Figure 5D). Next, we measured the percentage of aggregate-
positive cells (Figure 5E). With the decrease in mutant protein
levels observed by western blotting, we also observed decreases
in the number of protein aggregates. In untreated and siLUC-
treated fibroblasts, we observed 1–3 aggregates in about 60%
of cells. Protein aggregates localized mainly in the cytoplasm.
Rarely, cells with a high number of cytoplasmic protein
aggregates were observed and these cells also had nuclear
aggregates (Figure 2C). We observed significant decrease in
aggregate-positive cells up to 35–38% after treatment with A2M,
G2, and A2F (Figure 5E).
DISCUSSION
Molecular processes involved in the manifestation and
progression of polyQ diseases are not fully known; however, in
addition to the roles of mutant proteins, the roles of mutant
RNA in the pathomechanism of these diseases are increasingly
recognized. RNA toxicity mechanisms include the formation of
nuclear foci, protein sequestration within these foci triggering
alternative splicing events and gene expression defects as well
as aberrant biogenesis of small CAG-repeated RNAs (Galka-
Marciniak et al., 2012; Fiszer and Krzyzosiak, 2013; Martí, 2016).
Accordingly, the evaluation of new therapeutic approaches needs
to be performed at both RNA and protein levels. In this paper, we
proposed the application of microscopic techniques to monitor
changes in the RNA foci phenotype as well as changes in the level
and distribution of mutant proteins.
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FIGURE 6 | Proposed activity mechanisms of investigated CAG-repeat targeting ON reagents: miRNA-like siRNAs, ASO and LNA designed to interact
with CAG repeat tract. We summarize results from the analyses of reagents localization (Figure 1), HTT gene expression level (Figures 3, 5 and Supplementary
Figure S3), number of RNA foci per nucleus (Figure 4) and presence of huntingtin aggregates (Figure 5). miRNA-like siRNA (e.g., A2) act allele-selectively,
decreasing preferentially the translation of mutant protein and reducing number of RNA foci. ASO interacts in the nucleus with both normal and mutant HTT mRNA
lowering cellular level of RNA and protein. LNA exerts its activity in the nucleus decreasing slightly level of mRNA and reducing RNA foci number with only mild effect
on translation.
As mutant RNA foci are found in the nucleus, it was not clear
whether the ONs used would be able to affect RNA foci in any
way. According to recent studies, RNA foci are not static, but
rather dynamic structures, as shown for CGG and CUG repeats
(Querido et al., 2011; Strack et al., 2013), and mutant transcripts
were accessible to ON reagents. However, CAG RNA foci
differ in morphology and localization from RNA foci found in
other repeat expansion diseases (Wojciechowska and Krzyzosiak,
2011; Urbanek et al., 2016). Therefore, despite the successful
deconstruction of RNA foci in other repeat expansion diseases
(Supplementary Table S1), the ability to decrease CAG RNA
foci phenotype was not obvious. Our results demonstrated that
mutant HTT mRNA can be targeted by ON-based reagents in the
nucleus, as the decrease in number of RNA foci was observed.
Frontiers in Cellular Neuroscience | www.frontiersin.org 10 March 2017 | Volume 11 | Article 82
fncel-11-00082 March 24, 2017 Time: 16:45 # 11
Urbanek et al. Reduction of Huntington’s Disease RNA Foci
This may be explained by the dynamic nature of foci, but may also
indicate that the ONs examined in this study were incorporated
into nuclear speckles or, alternatively, targeted mutant transcripts
preventing their detention in nuclear speckles. The factors that
distinguish the reagents and determine their potential to reduce
RNA foci may be their cellular localization and mechanism of
their action (Figure 6 and Supplementary Table S3). Depending
on the chemical composition of CAG repeat-targeting ONs and
proteins that facilitate their binding to targets, they may possess
different ability to bind transcripts localized in the nucleus and
cytoplasm. Self-duplexing CAG-targeting siRNAs (A2) had little
effect on RNA levels, but significantly decreased mutant protein
levels and the number of RNA foci in analyzed time point. This
effect was not explained by the spectrum of mechanisms specified
in the section “Introduction.” This suggests that these siRNAs
bind to mutant transcripts in the cell nucleus, preventing them
from RNA foci formation as well as acting as translation repressor
in the cytoplasm. The observed reductions in RNA foci may
result also from earlier decreases in RNA levels which we cannot
observe at the analyzed time point after reagent transfection,
but was reported in our previous study (Fiszer et al., 2013).
CAG-targeting LNA decreased RNA levels, but very mildly, and
decreased RNA foci showing only slight influence on protein
levels. These results are in agreement with the postulated LNA-
modified ON function as an RNA blocker. LNA CTG interacting
with CAG repeats was shown to be active also in neuronal cells
and in vivo. LNA CTG treatment led to rescue of lowered levels
of striatal markers and improved motor functions in HD mouse
model. It was also shown that used ON was able to decrease
number of foci-positive cells (Rué et al., 2016). LNA CTG may
prevent mRNAs from RNA foci formation or release transcripts
from foci by interfering with interactions between CAG tracts
and proteins. The siRNA CAG/CUG, siHTT, and ASO CTG
decreased both RNA and protein levels and also decreased RNA
foci phenotype. This suggests that these ONs act, at least partially,
in the nucleus. However, none of these ONs had an allele-selective
effect on protein levels; therefore, they are not ideal for polyQ
diseases treatment.
The comprehensive approach used in this study to compare
various ONs in a single experimental model and conditions
enabled us to draw general conclusions about the decrease in
RNA foci phenotype. First, we observed that decreases in RNA
foci number are not directly correlated with decreases in HTT
mRNA levels. Using siHTT, we showed that despite a strong
decrease in transcript levels, the influence on RNA foci was less
than the effect observed for other tested ONs. These findings are
in agreement with earlier reports indicating that siRNA against
C9orf72RNA in ALS does not significantly alter RNA foci, despite
a significant decrease of C9orf72 RNA levels (Lagier-Tourenne
et al., 2013). On the other hand, ASO CTG, which targeted
the CAG repeat sequence, lowered the mRNA level, but also
most effectively decreased the number of foci in cells. Similarly,
ASOs targeting various regions of mutant C9orf72 RNA, both
repeats and specific sequence, led to decreases in the number
of cells containing foci as well as the number of foci per single
cell (Lagier-Tourenne et al., 2013). However, in our study, ASO
targeting specific sequence did not substantially affect the RNA
foci phenotype. We observed that CAG-targeting reagents were
more effective in decreasing the number of RNA foci compared
with other reagents. Repeat-targeting ONs are highly beneficial
because they can be used for the treatment of other polyQ
diseases, including several spinocerebellar ataxias (SCA1, SCA2,
SCA3, and SCA7). Moreover, with suitable base substitutions and
chemical modifications, these reagents can exhibit high allele-
selectivity.
CONCLUSION
Our results do not answer the question whether the observed
reduction in foci number results mainly from the inhibition of
new foci formation by ON binding to expanded CAG repeats
in nucleoplasm or from deconstruction of already existing foci
formed by mutant transcript which is detained in nuclear
speckles. The presented results demonstrate that the ONs bind
to mutant transcript already in cell nucleus and we hypothesize
that this binding altering accessibility of CAG repeats in mutant
transcript prevents its interaction with unidentified yet factor
responsible for transcript nuclear detention.
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